V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 220014028 | 220008490 | 1.64 | 8.6 | Disease modification (D) | 2017-11-09 | 2017-11-18 | Cyclophosphamide TBI Allograft | N | N | 220032149 | CYCLOPHOSPHAMIDE |
| 220014029 | 220008491 | 1.67 | null | Disease modification (D) | 2012-04-24 | 2014-03-21 | CYCLOPHOSPHAMIDE | N | N | 220032150 | CYCLOPHOSPHAMIDE |
| 220014030 | 220008492 | 1.69 | null | Curative (C) | 2014-03-28 | 2014-04-05 | Triple Intrathecal | N | N | 220032156 | TRIPLE INTRATHECAL |
| 220014032 | 220008499 | null | 63 | Curative (C) | null | 2014-06-01 | Methotrexate intrathecal | N | N | 220032158 | METHOTREXATE INTRATHECAL |
| 220014033 | 220014602 | 0 | 81.2 | null | 2013-07-29 | 2013-07-29 | BOSUTINIB | N | N | 220032159 | BOSUTINIB |
| 220014034 | 220008508 | 0 | 90 | Curative (C) | 2018-03-19 | 2018-03-20 | BOSUTINIB | 2 | null | 220032161 | BOSUTINIB |
| 220014035 | 220014605 | 0.96 | 79.4 | Curative (C) | 2015-10-25 | 2015-10-25 | AML Int Guide ADE 8+3+5 (2) | 02 | N | 220032164 | ADE |
| 220014037 | 220017986 | null | 68 | Not known (9) | 2014-06-16 | 2015-05-21 | FLAG | 02 | N | 220032170 | FLAG |
| 220014038 | 220017986 | 0 | null | Curative (C) | 2014-08-03 | 2014-08-03 | CYCLOPHOSPHAMIDE + FLUDARABINE | Y | N | 220032170 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014039 | 220008512 | 1.33 | 28.85 | Curative (C) | 2014-06-04 | 2017-11-15 | IDARUBICIN + TRETINOIN | N | null | 220032175 | IDARUBICIN + TRETINOIN |
| 220014040 | 220008512 | 1.55 | null | Curative (C) | 2016-06-24 | 2016-06-26 | ATG + Busulfan + Fludarabine | N | N | 220032175 | ATG + BUSULFAN + FLUDARABINE |
| 220014041 | 220008513 | 1.68 | null | Curative (C) | 2016-03-10 | 2016-03-10 | BOSUTINIB | Y | N | 220032180 | BOSUTINIB |
| 220014042 | 220008514 | null | null | null | 2018-04-24 | 2018-04-28 | ATG + Busulfan + Fludarabine | null | N | 220032181 | ATG + BUSULFAN + FLUDARABINE |
| 220014043 | 220008514 | 1.73 | 0 | Not known (9) | null | 2016-09-28 | BOSUTINIB | N | N | 220032181 | BOSUTINIB |
| 220014044 | 220008515 | 0 | null | Disease modification (D) | 2017-05-24 | 2017-06-09 | FLAG | 02 | N | 220032187 | FLAG |
| 220014045 | 220008515 | 1.71 | 127 | Disease modification (D) | 2017-11-10 | 2017-11-11 | ATG + Busulfan + Fludarabine | 2 | null | 220032187 | ATG + BUSULFAN + FLUDARABINE |
| 220014046 | 220008516 | 1.5 | 57.4 | null | 2013-03-16 | 2013-03-16 | RUXOLITINIB | 02 | N | 220032198 | RUXOLITINIB |
| 220014047 | 220008517 | 1.78 | 88 | Disease modification (D) | 2014-07-02 | 2014-07-02 | FLAG | 02 | N | 220032200 | FLAG |
| 220014048 | 220008517 | 1.69 | 29.3 | Adjuvant (A) | 2016-01-16 | 2016-01-16 | Idarubicin+Tretinoin Spanish Crse4 | N | N | 220032200 | IDARUBICIN + TRETINOIN |
| 220014049 | 220008517 | 1.65 | null | Curative (C) | null | 2018-04-12 | AML16 DA 3+8 | 02 | N | 220032200 | AML16 TRIAL |
| 220014050 | 220008520 | 1.86 | 85.7 | Curative (C) | 2014-06-09 | 2014-06-09 | IDARUBICIN + TRETINOIN | Y | N | 220032224 | IDARUBICIN + TRETINOIN |
| 220014051 | 220008521 | 1.7 | null | Curative (C) | 2015-08-27 | 2015-08-27 | AML Int Guide ADE 8+3+5 (2) | 2 | N | 220032225 | ADE |
| 220014052 | 220014611 | null | 65 | Curative (C) | 2014-08-21 | 2014-08-23 | AML16 DA 2+5 | 02 | N | 220032225 | AML16 TRIAL |
| 220014053 | 220014612 | 1.55 | 89.6 | Disease modification (D) | 2017-07-22 | 2017-07-27 | Triple Intrathecal | 2 | N | 220032227 | TRIPLE INTRATHECAL |
| 220014054 | 220014612 | 1.57 | 71.45 | Curative (C) | 2015-12-09 | 2015-12-12 | AML Int Guide ADE 8+3+5 (2) | 01 | N | 220032227 | ADE |
| 220014055 | 220008526 | 1.69 | 88.8 | Curative (C) | 2015-08-27 | 2015-08-30 | Triple / Double Intrathecal Therapy | N | N | 220032236 | TRIPLE INTRATHECAL |
| 220014056 | 220008530 | null | 55 | Curative (C) | 2014-12-14 | 2014-12-14 | CYCLOPHOSPHAMIDE | N | N | 220032252 | CYCLOPHOSPHAMIDE |
| 220014057 | 220008531 | 1.82 | 98 | Curative (C) | 2017-01-23 | 2017-01-23 | Triple Intrathecal | N | N | 220032254 | TRIPLE INTRATHECAL |
| 220014058 | 220008531 | 1.82 | null | Curative (C) | 2014-03-10 | 2014-04-10 | AML Int Guide ADE 10+3+5 (1) | N | null | 220032254 | ADE |
| 220014061 | 220008538 | 1.59 | 85 | Curative (C) | 2013-05-06 | 2013-05-22 | AML Int Guide ADE 8+3+5 (2) | N | N | 220032265 | ADE |
| 220014062 | 220008541 | 1.91 | 127 | Curative (C) | 2016-01-20 | 2016-01-20 | ATG + Busulfan + Fludarabine | N | null | 220032271 | ATG + BUSULFAN + FLUDARABINE |
| 220014063 | 220008542 | 1.65 | 55.8 | Curative (C) | 2013-07-29 | 2013-07-29 | ATG + Busulfan + Fludarabine | 2 | null | 220032272 | ATG + BUSULFAN + FLUDARABINE |
| 220014064 | 220008545 | 0 | 57.1 | Curative (C) | 2013-06-08 | 2013-07-13 | FLAG | N | N | 220032272 | FLAG |
| 220014065 | 220008545 | 0 | 75 | Curative (C) | 2017-07-17 | 2017-07-17 | AML Int Guide ADE 8+3+5 (2) | N | N | 220032272 | ADE |
| 220014066 | 220008547 | 1.72 | null | null | 2016-03-30 | 2016-03-30 | AML16 DA 3+8 | 02 | N | 220032287 | AML16 TRIAL |
| 220014067 | 220008548 | 1.68 | 85 | Curative (C) | 2015-09-26 | 2015-11-27 | RUXOLITINIB | Y | null | 220032288 | RUXOLITINIB |
| 220014068 | 220008549 | 1.8 | 0 | Curative (C) | 2014-12-30 | 2015-01-15 | CYCLOPHOSPHAMIDE + FLUDARABINE | 01 | N | 220032293 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014069 | 220008550 | null | 75 | Curative (C) | 2016-07-23 | 2016-07-24 | Idarubicin+Tretinoin Spanish Crse4 | 99 | N | 220032293 | IDARUBICIN + TRETINOIN |
| 220014070 | 220008551 | 1.68 | 99 | Disease modification (D) | 2012-07-04 | 2015-09-21 | FLAG | N | null | 220032309 | FLAG |
| 220014071 | 220008552 | 1.77 | 78.2 | Curative (C) | 2017-10-29 | 2017-10-29 | IDARUBICIN + TRETINOIN | 02 | N | 220032313 | IDARUBICIN + TRETINOIN |
| 220014072 | 220008555 | 1.72 | 16.6 | Curative (C) | 2018-08-08 | 2018-08-10 | Cyclophosphamide + Fludarabine IV | N | N | 220032316 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014073 | 220008557 | 1.73 | null | Curative (C) | 2016-10-15 | 2016-10-23 | CYCLOPHOSPHAMIDE + FLUDARABINE | N | N | 220032316 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014074 | 220008558 | 1.59 | 67.8 | Curative (C) | 2017-05-13 | 2017-05-13 | Triple Intrathecal | N | N | 220032319 | TRIPLE INTRATHECAL |
| 220014075 | 220008559 | 1.6 | null | Palliative (P) | 2014-06-18 | 2014-07-10 | Cyclophosphamide TBI Allograft | N | N | 220032328 | CYCLOPHOSPHAMIDE |
| 220014076 | 220008561 | 1.85 | null | Curative (C) | 2016-08-01 | 2016-08-01 | Cyclophosphamide+Fludara+TBI Allo | 02 | null | 220032328 | CYCLOPHOSPHAMIDE + FLUDARABINE |
| 220014077 | 220008562 | 1.77 | 76.6 | Disease modification (D) | 2015-09-26 | 2015-10-03 | Methotrexate intrathecal | N | N | 220032331 | METHOTREXATE INTRATHECAL |
| 220014078 | 220008564 | null | 0 | Disease modification (D) | 2016-01-07 | 2016-01-08 | Idarubicin+Tretinoin Spanish Crse1 | N | N | 220032333 | IDARUBICIN + TRETINOIN |
| 220014079 | 220008565 | 1.6 | 33 | Curative (C) | 2014-12-01 | 2014-12-05 | RUXOLITINIB | N | null | 220032344 | RUXOLITINIB |
| 220014080 | 220008566 | 1.79 | 105 | Curative (C) | 2017-03-29 | 2017-05-02 | AML16 DA 3+8 | 01 | N | 220032344 | AML16 TRIAL |
| 220014081 | 220008568 | 1.54 | 54.4 | Curative (C) | 2017-06-18 | 2017-08-05 | Cyclophosphamide+Fludara+TBI Allo | 2 | N | 220032350 | CYCLOPHOSPHAMIDE + FLUDARABINE |